


REGULATING THE CURE:



TOPICS ARISING OUT OF THE PRESCRIPTION OF DRUGS OFF-LABEL

ALBANY LAW SCHOOL JOURNAL
OF SCIENCE AND TECHNOLOGY
ANNUAL SYMPOSIUM

Friday, March 27th, 2009
8:30 a.m. - 1:05 p.m.

WHAT IS AN OFF-LABEL USE

The term "off-label" is generally used when a drug is prescribed for a disease or medical condition other than those described in the FDA-approved label.

Studies have shown that one out of every five prescriptions in America today is prescribed off-label. Additionally, a surprising 56% of all cancer patients have received some kind of off-label drug during the course of their treatment. The potential risks and gains to patients are great.

It is these risks that cause both legal and medical communities alike to debate the merits of off-label drug use, prescription, marketing, and tort liability.

SPEAKERS

MICHAEL P. KANE
*Professor, Albany College of Pharmacy
& Health Sciences*

ERIC T. CHAFFIN
*Bernstein Liebhard LLP
Former Assistant U.S. Attorney*

BYRON G. STIER
*Associate Professor of Law
Southwestern Law School*

DAN R. THOMPSON
*Professor of Surgery and Anesthesiology,
Core Faculty, Alden March Bioethics
Institute Chair, IRB*

MOLLIE G. HERTEL
U.S. Government Accountability Office

ARNOLD I. FRIEDE
McDermott Will & Emery

PATRICK JOSEPH IGOE
Registered Patent Attorney

SARAH L. SCARPACE
*Assistant Professor, Albany College of
Pharmacy & Health Sciences
President, NENYSCHP*

RAUL A. TABORA, JR.
*Ruffo, Tabora, Mainello & McKay
NYSBA Chair, E-Health &
Information Systems NYSBA Chair,
E-Health & Information Systems*



ALBANY LAW SCHOOL

80 New Scotland Avenue, Albany, New York 12208 Tel. 518-445-5855 albanylawjournal.org